Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etrumadenant Combinations in Breast and Gynecologic Cancers
NCT03719326Phase 1Completed
- Sponsor
- Arcus Biosciences
- Start
- Oct 2018
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of etrumadenant in triple-negative breast cancer (TNBC) and ovarian cancer (7 arms), sponsored by Arcus Biosciences. Primary endpoints: Incidence of Adverse Events and Incidence of dose-limiting toxicities at 28 days. Started Oct 2018; status: completed.
02
Drugs
etrumadenant
03
Conditions
triple-negative breast cancer (TNBC)ovarian cancer
Beyond the preview
Go deeper on NCT03719326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03719326.